Welocalize
Welocalize is recorded as a service provider in 27 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 27 trials · Latest update first
A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder
Sponsor Grin Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
Sponsor HepaRegeniX GmbH
- Start (EU)
- Latest update
- Estimated end
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
Multicenter Interventional Study: Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone
Sponsor Schneider Children's Medical Center Of Israel
- Start (EU)
- Latest update
- Estimated end
AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Not reported
- Latest update
- Estimated end
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2)
Sponsor Vifor Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants with Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT trial)
Sponsor NewAmsterdam Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy.
Sponsor Neuraxpharm Pharmaceuticals S.L.
- Start (EU)
- Latest update
- Estimated end
A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Not reported
- Latest update
- Estimated end
APG777-202 - A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
Sponsor Apogee Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study
Sponsor Gensight Biologics
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
Sponsor Sab Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label study to assess safety and efficacy of SZC in paediatric patients with hyperkalaemia
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter, Open‑label Trial to Evaluate the Long‑term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy.
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp
Sponsor Almirall S.A.
- Start (EU)
- Latest update
- Estimated end
Phase II Combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors
Sponsor Nerviano Medical Sciences S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Randomized, Placebo-controlled, 4-arm Parallel-group, Multiple-Dose Study to Assess Efficacy and Safety of Medical Cannabis Aerosol via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain
Sponsor Syqe Medical Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Sponsor Tyra Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Welocalize?
The 2026-10-09 snapshot links Welocalize to 27 distinct CTIS trials. Recorded services include Translations, Translation, Translation services, Linguistic validation, translation, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Welocalize?
The most frequently recorded therapeutic areas are Neurology, Respiratory, Blood Disorders, Cardiology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Welocalize conducted?
The linked trials record locations in 22 countries, including Spain, France, Germany, Poland, Italy. These are trial locations, not confirmed office locations or countries where Welocalize delivered services.
What can this page tell me about Welocalize's trial experience?
Browse 27 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Welocalize. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Welocalize
- Welocalize Inc.